PCI Biotech Holding ASA

PCIB

NO0010405640

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
1.618 ^NOK	0.00%		-4.82%	-22.77%

Feb. 14	PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Pci Biotech Initiates Field Testing of Its Proprietary Technology for Gene Therapy Manufacturing	CI

Financial calendar

August 31, 2023 at 04:27 am EDT

Financial calendar for PCI Biotech Holding ASA

FINANCIAL YEAR 2023


14.02.2024 - Quarterly Report - Q4


FINANCIAL YEAR 2024

28.08.2024 - Half-yearly Report
26.04.2024 - Annual Report
24.05.2024 - Annual General Meeting




Please note that PCI Biotech will report on a half yearly basis going forward
and the financial calendar for 2023 is amended accordingly.

Please note that the financial calendar may be subject to changes. 
Any changes will be communicated. 

For further information, please contact: Ronny Skuggedal, CEO, rs@pcibiotech.no,
Mobile: +47 9400 5757 PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
For more information visit: www.pcibiotech.com


This information is published pursuant to the requirements set out in the
Continuing obligations.

Click here for more information

Latest news about PCI Biotech Holding ASA

PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Pci Biotech Initiates Field Testing of Its Proprietary Technology for Gene Therapy Manufacturing	23-10-13	CI
PCI Biotech Holding ASA Announces European Patent Office Intends to Grant A New Patent Covering Delivery of mRNA	23-09-07	CI
PCI Biotech Holding ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
PCI Biotech Holding ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
PCI Biotech Holding ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
PCI Biotech Holding ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
PCI Biotech Holding ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Transcript : PCI Biotech Holding ASA, Q2 2022 Earnings Call, Aug 31, 2022	22-08-31
PCI Biotech Announces PH II Clinical Trail Update	22-08-18	CI
PCI Biotech Holding ASA Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Transcript : PCI Biotech Holding ASA, Q1 2022 Earnings Call, May 11, 2022	22-05-11
PCI Biotech CEO to Step Down to Join Exact Therapeutics	22-03-28	MT
PCI Biotech Holding ASA Announces Resignation on Per Walday as Chief Executive Officer	22-03-28	CI
PCI Biotech Holding ASA(OB:PCIB) dropped from S&P Global BMI Index	22-03-21	CI
PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-18	CI
PCI Biotech Holding ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-18	CI
Transcript : PCI Biotech Holding ASA, Q4 2021 Earnings Call, Feb 18, 2022	22-02-18
Transcript : PCI Biotech Holding ASA - Special Call	22-01-25
PCI Biotech Loses 10% As It Discontinues Cancer Trial To Focus On Immunotherapies	22-01-24	MT
PCI Biotech Holding ASA Provides Update on the RELEASE Trial	22-01-24	CI
PCI Biotech Announces Publication of Preclinical Tuberculosis Results	22-01-11	CI
Norway's PCI Biotech, South Korea-based MDimune Join Preclinical Research Partnership	22-01-05	MT
PCI Biotech and MDimune Announce Research Collaboration Agreement	22-01-05	CI

PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotechâs product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PCI BIOTECH HOLDING ASA	-22.77%	5.47M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B